Biocon Ltd. News and Updates

Name: Latest research reports of Biocon Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 1
Author: Geojit BNP Paribas

Keep track of all breaking news on Biocon Ltd. from all sources in a single place.

Biocon Ltd.

18 Oct 2025, 12:04PM

356.15

-0.57%

Biocon chief Kiran Mazumdar-Shaw slams IndiGo's food menu, sparks debate

Business Standard

The airline ensured that it would enhance the offerings and thanked her for sharing feedback, noting that customer opinions help them improve

Biocon Ltd. has an average target of 354.40 from 5 brokers.

Biocon Ltd.

14 Oct 2025

356.15

-0.57%

Biocon's Kiran Mazumdar-Shaw flags Bengaluru road woes; minister responds

Business Standard

Responding to Shaw's criticism, Karnataka minister Priyank Kharge said he was unsure which part of Bengaluru her overseas visitor has seen

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

Biocon Ltd.

07 Oct 2025

356.15

-0.57%

Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin

Business Standard

The USFDA's tentative approval means Biocon Pharma's Rifaximin 550 mg meets regulatory requirements but cannot be marketed in the US yet due to patents or exclusivity on the original drug

Biocon Ltd. is trading above its 200 day SMA of 353.4

Biocon Unit Gets USFDA Nod For Generic Rifaximin Tablets Used To Treat IBS-D

NDTV Profit | 07 Oct 2025 1 more

Biocon Ltd.

03 Oct 2025

356.15

-0.57%

BIOCON LTD

Sell: Biocon Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Biocon Ltd is a biopharmaceutical company that develops therapies for chronic diseases such as autoimmune, cancer and diabetes. The company has developed and introduced novel biologics, biosimilars, differentiated small molecules and affordable recombinant human insulin and analogues. In Q1FY26, Biocon's consolidated revenue grew 14.8% YoY to Rs. 3,942cr, driven...

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

Biocon Ltd.

11 Sep 2025

356.15

-0.57%

Biocon expands US footprint with new Cranbury manufacturing facility

Business Standard

Biocon inaugurated its first US manufacturing facility in Cranbury through Biocon Generics, expanding its global footprint and strengthening supply chains for essential therapies

Institutional Investors have increased holdings from 21.40% to 28.87% in Jun 2025 qtr.

Biocon inaugurates first manufacturing facility in New Jersey's Cranbury

Business Standard | 11 Sep 2025 1 more

Biocon Ltd.

05 Sep 2025

356.15

-0.57%

Biocon shares gain 2% after USFDA inspection at Bengaluru facility; details

Business Standard

The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses

Biocon Ltd. is trading above its 200 day SMA of 353.4

Biocon Ltd.

11 Aug 2025

356.15

-0.57%

Biocon shares slip 3% as Q1 results miss estimates; should you sell?

Business Standard

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

Number of FII/FPI investors increased from 305 to 333 in Jun 2025 qtr.

Biocon Ltd.

11 Aug 2025

356.15

-0.57%

Result Update:Biocon

Buy: Biocon Ltd.

Target

Axis Direct

We maintain our BUY rating on the stock with a target price of Rs 380/share, implying an 11% upside potential from the CMP.

Promoters have decreased holdings from 60.64% to 54.45% in Jun 2025 qtr

Biocon Ltd.

09 Aug 2025

356.15

-0.57%

Margin pressure persists

Sell: Biocon Ltd.

Target

ICICI Securities Limited

Biocon’s Q1FY26 performance was marred by operating cost of new facilities for generic division and lower-thananticipated margins in biologics division.